Lasa Supergenerics Limited Total Liabilities
Lasa Supergenerics Limited total liabilities. Based on the latest financial reports, Lasa Supergenerics Limited (LASA) has total liabilities worth Rs152.61 Million INR (≈ $1.65 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Lasa Supergenerics Limited to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Lasa Supergenerics Limited (2017–2025)
Total liabilities of Lasa Supergenerics Limited from 2017 to 2025. This chart illustrates how Lasa Supergenerics Limited's total liabilities have evolved over time, based on quarterly financial data. Explore LASA strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Lasa Supergenerics Limited Competitors by Total Liabilities
The table below lists competitors of Lasa Supergenerics Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Preecha Group Public Company Limited
BK:PRECHA
|
Thailand | ฿238.63 Million |
|
Neurizer Ltd
AU:NRZ
|
Australia | AU$60.54 Million |
|
Dongwon Systems Corp
KO:014825
|
Korea | ₩701.13 Billion |
|
Lithium Energi Exploration Inc
V:LEXI
|
Canada | CA$7.50 Million |
|
DecideAct A/S
CO:ACT
|
Denmark | Dkr16.53 Million |
|
Jianzhi Education Technology Group Company Limited American Depositary Shares
NASDAQ:JZ
|
USA | $31.75 Million |
|
Dongbu Corp
KO:005965
|
Korea | ₩1.14 Trillion |
|
Mobi724 Global Solutions Inc
V:MOS
|
Canada | CA$15.11 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Lasa Supergenerics Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Lasa Supergenerics Limited balance sheet assets.
Liquidity & Leverage Metrics
Lasa Supergenerics Limited Total Liabilities Ratios Explained
Lasa Supergenerics Limited total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.03 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Lasa Supergenerics Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Lasa Supergenerics Limited (2017–2025)
The table below shows the annual total liabilities of Lasa Supergenerics Limited from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | Rs178.19 Million ≈ $1.93 Million |
-67.12% |
| 2024-03-31 | Rs541.92 Million ≈ $5.86 Million |
+18.92% |
| 2023-03-31 | Rs455.69 Million ≈ $4.93 Million |
-11.15% |
| 2022-03-31 | Rs512.87 Million ≈ $5.55 Million |
+4.79% |
| 2021-03-31 | Rs489.43 Million ≈ $5.29 Million |
-45.93% |
| 2020-03-31 | Rs905.23 Million ≈ $9.79 Million |
-40.91% |
| 2019-03-31 | Rs1.53 Billion ≈ $16.57 Million |
-9.59% |
| 2018-03-31 | Rs1.69 Billion ≈ $18.32 Million |
+10.92% |
| 2017-03-31 | Rs1.53 Billion ≈ $16.52 Million |
-- |
About Lasa Supergenerics Limited
Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-… Read more